The YAP/TEAD Hippo signaling pathway has emerged as a compelling therapeutic target for neurodegenerative diseases. Yes-associated protein (YAP) and its paralog TAZ (WWTR1) are transcriptional coactivators that regulate cell survival, neurogenesis, and cellular stress responses. In neurodegeneration, YAP/TAZ activity is suppressed by amyloid-beta, tau pathology, and alpha-synuclein aggregation, contributing to neuronal death.
YAP/TEAD pathway modulators aim to restore YAP nuclear activity and promote neuroprotection through multiple mechanisms. This page covers the scientific rationale, drug candidates, and clinical development status for this emerging therapeutic approach.
In Alzheimer's disease and Parkinson's disease, YAP/TAZ activity is suppressed through multiple mechanisms:
Alzheimer's Disease:
- Amyloid-beta reduces YAP nuclear localization in neurons
- Hyperphosphorylated tau sequesters YAP in the cytoplasm
- Age-related decline in Hippo pathway activity correlates with reduced neurogenesis
Parkinson's Disease:
- Alpha-synuclein aggregation suppresses YAP/TAZ activity
- Mitochondrial toxins reduce YAP nuclear localization
- YAP is particularly important for dopaminergic neuron survival
YAP activation promotes multiple protective functions:
- Anti-apoptotic signaling: YAP promotes expression of Bcl-2, survivin, and other survival genes
- Oxidative stress response: YAP senses and responds to oxidative signals
- Energy homeostasis: YAP connects to AMPK signaling to monitor cellular energy status
- Neurogenesis: YAP supports neural stem cell proliferation and differentiation
- Autophagy regulation: YAP-TEAD complexes regulate autophagy gene expression
The challenge in targeting YAP/TEAD is achieving neuroprotection without promoting oncogenic effects. YAP's role in cell proliferation makes complete pathway activation potentially risky. However, selective neuronal activation or cell-type specific targeting may provide therapeutic benefit while minimizing cancer risk.
¶ Drug Candidates
Mechanism: Verteporfin is an FDA-approved photosensitizer for photodynamic therapy that has been found to activate YAP by inhibiting its interaction with LATS1/2 kinases. It promotes YAP nuclear translocation and transcriptional activity.
Preclinical Evidence:
- Reduces neuronal apoptosis in amyloid-beta toxicity models
- Protects against oxidative stress in neuronal cultures
- Promotes neurogenesis in hippocampal progenitor cells
Clinical Status: Currently in preclinical development for neurodegeneration. The established safety profile from ophthalmic use is advantageous, though CNS penetration remains a challenge.
Challenges:
- Phototoxicity concerns with systemic administration
- Limited understanding of dosing for neuroprotection
- Need for brain-penetrant formulations
Mechanism: TT-10 is a small molecule YAP activator that promotes YAP nuclear localization and transcriptional activity without significant phototoxicity.
Preclinical Evidence:
- Neuroprotection in MPTP Parkinson's disease model
- Reduced dopaminergic neuron loss
- Improved motor function in animal studies
Development Status: Preclinical stage, being developed for Parkinson's disease and related disorders.
Advantages:
- Designed specifically for YAP activation
- Better safety profile than verteporfin
- Potential for oral administration
Mechanism: CA3 is a TEAD family inhibitor that blocks YAP-TEAD transcriptional activity. While this may seem counterintuitive, in certain disease contexts reducing pro-inflammatory TEAD activity in glial cells while sparing neuronal YAP may be beneficial.
Rationale: YAP has context-dependent effects—protective in neurons but pro-inflammatory in microglia. Selective TEAD inhibition may reduce neuroinflammation without affecting neuronal YAP.
Preclinical Evidence:
- Reduced microglial activation in models
- Decreased pro-inflammatory cytokine production
- Protection of neurons from glial-mediated toxicity
Challenges:
- Achieving cell-type selectivity
- Balancing inflammatory vs. protective effects
- Understanding optimal inhibition level
flowchart TD
A["YAP/TAZ Pathway Modulators"] --> B["Verteporfin"]
A --> C["TT-10"]
A --> D["CA3 TEAD Inhibitor"]
B --> E["Inhibit LATS1/2"]
E --> F["YAP Nuclear Translocation"]
F --> G["TEAD Transcription"]
G --> H["Anti-apoptotic Genes"]
G --> I["Antioxidant Genes"]
C --> J["Promote YAP Activation"]
J --> F
D --> K["Block TEAD Activity"]
K --> L["Reduced Neuroinflammation"]
L --> M["Microglial YAP/TAZ Inhibition"]
H --> N["Neuroprotection"]
I --> N
M --> N
YAP/TAZ modulators address multiple aspects of AD pathophysiology:
- Amyloid toxicity: Restore YAP activity suppressed by Aβ
- Tau pathology: Prevent YAP sequestration by phosphorylated tau
- Neurogenesis: Support hippocampal neurogenesis
- Oxidative stress: Enhance antioxidant response
In PD, YAP/TAZ modulators target:
- Dopaminergic neuron survival: Protect vulnerable SNpc neurons
- Alpha-synuclein toxicity: Restore activity suppressed by aggregation
- Mitochondrial dysfunction: Leverage AMPK-YAP connection
- Neuroinflammation: Modulate microglial activation
- Amyotrophic lateral sclerosis (ALS): Support motor neuron survival
- Huntington's disease: Address polyglutamine toxicity
- Multiple system atrophy: Target oligodendrocyte dysfunction
YAP/TEAD modulators may be combined with:
| Combination |
Rationale |
| Anti-aggregation therapy |
Synergistic with protein clearance |
| Antioxidants |
Complement oxidative stress response |
| Neurotrophic factors |
Support neuronal survival |
| Anti-inflammatory agents |
Target neuroinflammation |
¶ Challenges and Future Directions
- CNS penetration: Most YAP-targeting compounds have limited brain penetration
- Cell-type specificity: Achieving selective modulation in neurons vs. glia
- Safety concerns: Balancing neuroprotection with oncogenic potential
- Biomarker development: No validated biomarkers for pathway activity
- Timing: Optimal intervention window unclear
- Phosphodiesterase inhibitors: Some PDEs affect YAP activity
- Mechanical stimulation: Exercise and vibration may activate pathway
- Gene therapy: AAV-mediated YAP delivery
- Protein-protein interaction disrupters: Novel small molecules
| Drug |
Company |
Stage |
Indication |
| Verteporfin |
Various (repurposing) |
Preclinical |
AD, PD |
| TT-10 |
Academic/Industry |
Preclinical |
PD |
| CA3 |
Research |
Preclinical |
Neuroinflammation |
YAP/TEAD pathway modulators represent a promising therapeutic approach for neurodegenerative diseases. By restoring YAP activity suppressed by disease pathology, these compounds may provide neuroprotection through multiple mechanisms. While significant challenges remain—particularly regarding CNS penetration and safety—the strong mechanistic rationale and growing preclinical evidence support continued development.
The dual role of YAP in both neuronal survival and neuroinflammation adds complexity but also provides opportunities for selective targeting. Future work should focus on developing brain-penetrant compounds, achieving cell-type specificity, and identifying biomarkers for patient selection.
- YAP/TAZ in neuronal survival and neurodegeneration (2024)
- Hippo pathway in Alzheimer's disease (2024)
- YAP/TEAD inhibitors in cancer therapy (2024)
- Verteporfin neuroprotection mechanisms (2023)
- TT-10 in Parkinson's disease models (2023)
- Hippo pathway and neuroinflammation (2024)
- AMPK-YAP signaling in energy stress (2024)
- YAP in dopaminergic neuron survival (2023)
- Tau pathology and YAP sequestration (2023)
- Alpha-synuclein and YAP/TAZ activity (2024)